Article
Endothelin receptor antagonist reduces markers of PCa
Author(s):
Chicago-The selective endothelin receptor antagonist atrasentan significantly attenuates changes in biochemical markers of bone metabolism and disease progression in a group of patients with advanced hormone-refractory prostate cancer that had progressed on placebo, according to the results of a randomized clinical trial.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Maria Uloko, MD, on the need for better education on female sexual dysfunction
Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
Alternative treatments and patient communication for genitourinary syndrome of menopause
Yahir A. Santiago-Lastra, MD, discusses barriers to vaginal estrogen access
Expert discusses genitourinary syndrome of menopause guidelines
Karyn S. Eilber, MD, shares her reaction to genitourinary syndrome of menopause guidelines
Urology CNP discusses sensitivity in communication, physical exam
Ekene Enemchukwu, MD, on the need for better education on GSM, vaginal estrogen
Urologist discusses drug cost savings, price transparency
Ekene Enemchukwu, MD, on underutilization of vaginal estrogen for GSM
Related Content
